Irene Kirolos1, David Jones1, Kirstin Hesterberg1, Charles Yarn1, Rami N Khouzam1, Yehoshua C Levine2,3. 1. Department of Medicine, Division of Cardiovascular Diseases, Cardiovascular Institute, Methodist Le Bonheur Healthcare System, University of Tennessee Health Science Center, Memphis, TN, USA. 2. Department of Medicine, Division of Cardiovascular Diseases, Cardiovascular Institute, Methodist Le Bonheur Healthcare System, University of Tennessee Health Science Center, Memphis, TN, USA. ylevine@uthsc.edu. 3. Methodist le Bonheur Healthcare, Division of Cardiology, University of Tennessee Health Science Center, 1211 Union Avenue, Suite 475, Memphis, TN, 38104, USA. ylevine@uthsc.edu.
Abstract
PURPOSE OF REVIEW: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. RECENT FINDINGS: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy-rather than ineffectiveness of WCD therapy-remains an important theme. The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.
PURPOSE OF REVIEW: The wearable cardioverter defibrillator (WCD) or LifeVest may protect against sudden cardiac death (SCD) in patients awaiting insertion of an implantable cardioverter defibrillator (ICD). The purpose of this communication is to review the rationale behind WCD therapy and to critically analyze recent data regarding its clinical efficacy. We seek to provide evidence-based recommendations regarding the potential role of the WCD in certain populations. RECENT FINDINGS: The only randomized controlled trial that evaluated WCD therapy did not demonstrate a reduced rate of arrhythmic death in patients prescribed the WCD during the first 90-day post-myocardial infarction (MI). However, when considering trial results alongside previous retrospective data, patient noncompliance with WCD therapy-rather than ineffectiveness of WCD therapy-remains an important theme. The uncertainty of data regarding the use of WCD therapy in patients during ICD waiting periods should be considered as part of the shared decision processes between healthcare providers and patients. Higher rates of adherence are needed to ensure efficiency. Well-designed future studies with appropriate cost-effectiveness analyses are indicated to define the clinical efficacy of WCD therapy on arrhythmic and non-arrhythmic morbidity and mortality in patients who are not yet candidates for ICDs.
Authors: Stefan H Hohnloser; Karl Heinz Kuck; Paul Dorian; Robin S Roberts; John R Hampton; Robert Hatala; Eric Fain; Michael Gent; Stuart J Connolly Journal: N Engl J Med Date: 2004-12-09 Impact factor: 91.245
Authors: Mina K Chung; Steven J Szymkiewicz; Mingyuan Shao; Edwin Zishiri; Mark J Niebauer; Bruce D Lindsay; Patrick J Tchou Journal: J Am Coll Cardiol Date: 2010-07-13 Impact factor: 24.094
Authors: Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip Journal: N Engl J Med Date: 2005-01-20 Impact factor: 91.245
Authors: William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub Journal: N Engl J Med Date: 2007-03-26 Impact factor: 91.245
Authors: Scott D Solomon; Steve Zelenkofske; John J V McMurray; Peter V Finn; Eric Velazquez; George Ertl; Adam Harsanyi; Jean L Rouleau; Aldo Maggioni; Lars Kober; Harvey White; Frans Van de Werf; Karen Pieper; Robert M Califf; Marc A Pfeffer Journal: N Engl J Med Date: 2005-06-23 Impact factor: 91.245
Authors: Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy Journal: N Engl J Med Date: 2008-09-04 Impact factor: 91.245
Authors: Arthur M Feldman; Helmut Klein; Patrick Tchou; Srinivas Murali; W Jackson Hall; Donna Mancini; John Boehmer; Mark Harvey; M Stephen Heilman; Steven J Szymkiewicz; Arthur J Moss Journal: Pacing Clin Electrophysiol Date: 2004-01 Impact factor: 1.976
Authors: Gerhard Steinbeck; Dietrich Andresen; Karlheinz Seidl; Johannes Brachmann; Ellen Hoffmann; Dariusz Wojciechowski; Zdzisława Kornacewicz-Jach; Beata Sredniawa; Géza Lupkovics; Franz Hofgärtner; Andrzej Lubinski; Mårten Rosenqvist; Alphonsus Habets; Karl Wegscheider; Jochen Senges Journal: N Engl J Med Date: 2009-10-08 Impact factor: 91.245